We propose rituximab as a first-line therapy for pemphigus vulgaris and steroid-dependent
bullous pemphigoid with or without systemic steroids. A brief review of the literature …

Background The use of rituximab for refractory autoimmune blistering diseases is
increasing. Data related to rituximab for the treatment of mucous membrane pemphigoid …

Background: Although rituximab is known to be effective in the treatment of pemphigus, its
role in subepidermal autoimmune blistering diseases is unclear and currently limited to off …

Rituximab is a chimeric human-mouse monoclonal anti-CD20 antibody initially developed to
treat B cell lymphoproliferative disorders (1). It is now increasingly being used for the …

Autoimmune blistering diseases are associated with autoantibodies to desmosomal
(pemphigus group) or hemidesmosomal proteins (autoimmune subepidermal blistering …

BACKGROUND: Rituximab has been increasingly used in autoimmune blistering
dermatoses, mainly in pemphigus. However, only a few larger case series are available on …

The conventional treatment for the autoimmune bullous skin diseases is broad-spectrum
immunosuppressive regimen typically combining systemic corticosteroids with adjuvant …

IN THIS ISSUE OF THE ARCHIVES, LE ROUX-VILLET ET al1 describe 25 patients with
mucous membrane pemphigoid (MMP) who had either extensive disease for a mean of 32 …

Background Bullous pemphigoid (BP) is the most common autoimmune blistering disease
requiring treatment with immunosuppressive medications; however, finding a therapy that …

Background Intolerably high doses of systemic corticosteroids and additional
immunosuppressants may be required to control disease activity in autoimmune bullous skin …